| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 10/01/2025 | 13:17 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 10/01/2025 | 13:15 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 20/12/2024 | 20:15 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 03/12/2024 | 12:00 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to incl | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 18/11/2024 | 13:00 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 14/11/2024 | 03:04 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 14/11/2024 | 03:01 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 14/11/2024 | 00:30 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 13/11/2024 | 22:01 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces New Employment Inducement Grants | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 12/11/2024 | 13:55 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 06/11/2024 | 14:20 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 06/11/2024 | 14:00 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 05/11/2024 | 22:01 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 04/11/2024 | 22:01 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024 | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 24/10/2024 | 12:00 | GlobeNewswire Inc. | Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 23/10/2024 | 14:00 | GlobeNewswire Inc. | Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024 | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 26/08/2024 | 14:02 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 26/08/2024 | 14:00 | GlobeNewswire Inc. | Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 14/08/2024 | 22:06 | Edgar (US Regulatory) | Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 07/08/2024 | 12:03 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 07/08/2024 | 12:00 | Edgar (US Regulatory) | Form DEFR14A - Revised definitive proxy soliciting materials | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 06/08/2024 | 13:00 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 31/07/2024 | 15:10 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 23/07/2024 | 14:00 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 23/07/2024 | 13:30 | GlobeNewswire Inc. | Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 10/07/2024 | 23:00 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 10/07/2024 | 22:05 | Edgar (US Regulatory) | Form 424B7 - Prospectus [Rule 424(b)(7)] | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 08/07/2024 | 14:00 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 28/06/2024 | 14:00 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |
| 03/06/2024 | 22:02 | GlobeNewswire Inc. | Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 | NASDAQ:RYTM | Rhythm Pharmaceuticals Inc |